TerminatedPhase 2

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Stopped: Business Decision

United States4 participantsStarted 2019-05-22

Plain-language summary

The objective of this study is to compare the efficacy and safety of RGN-137 topical gel with that of placebo gel for treatment of junctional epidermolysis bullosa (JEB) or dystrophic epidermolysis bullosa (DEB).

Who can participate

Age range4 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Index wounds must have a surface area between 5 cm2 and 50 cm2, inclusive at the screening visit
✓. The index wounds selected as pairing must be relatively matched in terms of size and location

What they're measuring

Time to achieving 50% reduction in area of each index wound from Day 1 up to Day 84.

Timeframe: up to Day 84

Trial details

NCT IDNCT03578029

SponsorLenus Therapeutics, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-09-01

View on ClinicalTrials.gov More Junctional Epidermolysis Bullosa trials